1Mita C,Chatelut E,Bekradda M, et al. Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies[J]. Ann Oncol, 2003,14( 12):1776.
2Elias D,Bonnay M,Puizillou JM, et al. Heated intra-operative intraperitoneal Oxaliplitin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution[J]. Ann Oncol, 2002,13(2):267.
3Extra JM, Marty M, Brienza S,et al. Pharmacokinetics and safety profile of oxaliplatin [J]. Semin Oncol,1998,25(2 Suppl 5):13--22.
4Beliber H,de Gramont A. Oxaliplatin plus 5-fluorou-racil : clinical experience in patients with advanced colorectal cancer [J]. Semin Oncol, 1998,25 (2 Suppl 5) :32--39.
5André T, Bensmaine MA, Louvet C, et al. Multicenter phaseⅡstudy of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen[J]. J Clin Oncol, 1999,1
6Woynarowski JM, Faivre S, Herzig MC, et al. Oxaliplatin-induced damage of cellular DNA[J]. Mol Pharmacol, 2000,58(5):920
7Massari C, brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function[J]. Cancer Chemother Pharmacol, 2000,45:157
8Levi F, Metzger G, Massari C, et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspects[J].Clin Pharmacokinet,2000,38(1):1
9de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients[J]. Br J Cancer,2003,88(8):1199
10Alliot C, Messouak D, Beets C, et al. Severe anaphylactic reaction to oxaliplatin[J]. Clin Oncol (R Coll Radiol),2001,13(3):236
5Kohn EC.Angiogenesis in ovarian carcinoma:a formidablebiomarker[J].Cancer,1997,80( 12):2219-2221.
6Geva E,Jaffe RB.Role of vascular endothelial growth factor inovarian physiology and pathology[J].Fertil Steril,2000,74 ( 3 ):429438.
7Belotti D,Paganoni P,Manenti L,et al.Matrix metalloproteinases(MMP9 and MMP2 ) induce the release of vascular endothelialgrowth factor ( VEGF) by ovarian carcinoma cells:implications forascites formation[J].Cancer Res,2003,63( 17):5224-5229.
8Falk MH,Issels RD.Hyperthermia in oncology[J].Int JHyperthermia,2001,17( 1 ):1-18.
9Elias D,Bonnay M,Puizillou JM,et al.Heated intra-operativeintraperitoneal oxaiiplatin after complete resection of peritonealcarcinomatosis:pharmacokinetics and tissue distribution[J].Ann0ncol,2002'13(2):267-272.
